{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:47Z","timestamp":1792783427244,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"University of Southern California","id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"DOI":"10.1007\/s40273-026-01668-3","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:21:35Z","timestamp":1791552095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Waiting for Trial Evidence or Using Real-World Evidence: Trade-Offs for Coverage with Evidence Development"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7483-2115","authenticated-orcid":false,"given":"Boshen","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar","family":"Zafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"4","key":"1668_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1017\/S0266462307070651","volume":"23","author":"J Hutton","year":"2007","unstructured":"Hutton J, Trueman P, Henshall C. Coverage with evidence development: an examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007;23(4):425\u201332. https:\/\/doi.org\/10.1017\/S0266462307070651.","journal-title":"Int J Technol Assess Health Care"},{"issue":"7","key":"1668_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jval.2018.11.010","volume":"22","author":"XGLV Pouwels","year":"2019","unstructured":"Pouwels XGLV, Grutters JPC, Bindels J, Ramaekers BLT, Joore MA. Uncertainty and coverage with evidence development: does practice meet theory? Value Health. 2019;22(7):799\u2013807.","journal-title":"Value Health"},{"issue":"3","key":"1668_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jval.2011.12.013","volume":"15","author":"S Walker","year":"2012","unstructured":"Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570\u20139.","journal-title":"Value Health"},{"key":"1668_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/hec.4478","volume":"31","author":"M Drummond","year":"2022","unstructured":"Drummond M, Federici C, Reckers-Droog V, Torbica A, Blankart CR, Ciani O, et al. Coverage with evidence development for medical devices in Europe: can practice meet theory? Health Econ. 2022;31:179\u201394.","journal-title":"Health Econ"},{"issue":"5","key":"1668_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1177\/17407745251313979","volume":"22","author":"M Mooghali","year":"2025","unstructured":"Mooghali M, Moneer O, Janda G, Ross JS, Dhruva SS, Ramachandran R. Characterization of studies considered and required under Medicare\u2019s coverage with evidence development program. Clin Trials. 2025;22(5):619\u201325. https:\/\/doi.org\/10.1177\/17407745251313979.","journal-title":"Clin Trials"},{"key":"1668_CR6","unstructured":"National Institute for Health and Care Excellence (NICE). Introduction to real-world evidence in NICE decision making. 2022. https:\/\/www.nice.org.uk\/corporate\/ecd9\/chapter\/introduction-to-real-world-evidence-in-nice-decision-making. Accessed 8 Sep 2026."},{"issue":"2","key":"1668_CR7","first-page":"24","volume":"4","author":"W Atkinson","year":"2007","unstructured":"Atkinson W. The impact of CED on private payers. Biotechnol Healthc. 2007;4(2):24.","journal-title":"Biotechnol Healthc"},{"issue":"8","key":"1668_CR8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jval.2019.02.011","volume":"22","author":"D Carter","year":"2019","unstructured":"Carter D, Merlin T, Hunter D. An ethical analysis of coverage with evidence development. Value Health. 2019;22(8):878\u201383.","journal-title":"Value Health"},{"issue":"1","key":"1668_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-024-03041-z","volume":"19","author":"VW Dayer","year":"2024","unstructured":"Dayer VW, Drummond MF, Dabbous O, Toumi M, Neumann P, Tunis S, et al. Real-world evidence for coverage determination of treatments for rare diseases. Orphanet J Rare Dis. 2024;19(1):47.","journal-title":"Orphanet J Rare Dis"},{"key":"1668_CR10","doi-asserted-by":"publisher","unstructured":"Grogan J. Medicare\u2019s \u201cCoverage With Evidence Development\u201d: A Barrier to Patient Access and Innovation. Health Aff airs Forefront. May 1, 2023. https:\/\/doi.org\/10.1377\/forefront.20230428.275268","DOI":"10.1377\/forefront.20230428.275268"},{"issue":"12","key":"1668_CR11","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2217\/cer-2018-0066","volume":"7","author":"G Hampson","year":"2018","unstructured":"Hampson G, Towse A, Dreitlein WB, Henshall C, Pearson SD. Real-world evidence for coverage decisions: opportunities and challenges. J Comp Eff Res. 2018;7(12):1133\u201343.","journal-title":"J Comp Eff Res"},{"key":"1668_CR12","unstructured":"Goldman DP, Van Nuys K, Cheng W-H, Hl\u00e1vka JP, Pani L, Chassang S, et al. A new model for pricing drugs of uncertain efficacy. NEJM Catal. 2018;4(6)."},{"key":"1668_CR13","unstructured":"Centers for Medicare & Medicaid Services. Proposed guidance document: study protocols that use real-world data. 2025. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/medicare-coverage-document.aspx?mcdid=39. Accessed 8 Sep 2026."},{"issue":"3","key":"1668_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/jrsssa\/qnae039","volume":"187","author":"R Kundu","year":"2024","unstructured":"Kundu R, Shi X, Morrison J, Barrett J, Mukherjee B. A framework for understanding selection bias in real-world healthcare data. J R Stat Soc Ser A Stat Soc. 2024;187(3):606\u201335. https:\/\/doi.org\/10.1093\/jrsssa\/qnae039.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"2","key":"1668_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","volume":"23","author":"E Fenwick","year":"2020","unstructured":"Fenwick E, Steuten L, Knies S, et al. Value of information analysis for research decisions \u2014 an introduction: report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value Health. 2020;23(2):139\u201350.","journal-title":"Value Health"},{"issue":"3","key":"1668_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jval.2020.01.004","volume":"23","author":"C Rothery","year":"2020","unstructured":"Rothery C, Strong M, Koffijberg HE, et al. Value of information analytical methods: report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value Health. 2020;23(3):277\u201386. https:\/\/doi.org\/10.1016\/j.jval.2020.01.004.","journal-title":"Value Health"},{"issue":"5","key":"1668_CR17","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/ije\/dyab061","volume":"50","author":"JM Petersen","year":"2021","unstructured":"Petersen JM, Ranker LR, Barnard-Mayers R, MacLehose RF, Fox MP. A systematic review of quantitative bias analysis applied to epidemiological research. Int J Epidemiol. 2021;50(5):1708\u201330.","journal-title":"Int J Epidemiol"},{"key":"1668_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076365","volume":"385","author":"JP Brown","year":"2024","unstructured":"Brown JP, Hunnicutt JN, Ali MS, et al. Quantifying possible bias in clinical and epidemiological studies with quantitative bias analysis: common approaches and limitations. BMJ. 2024;385:e076365.","journal-title":"BMJ"},{"issue":"5","key":"1668_CR19","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/ije\/dyaa127","volume":"49","author":"A Cusson","year":"2020","unstructured":"Cusson A, Infante-Rivard C. Bias factor, maximum bias and the E-value: insight and extended applications. Int J Epidemiol. 2020;49(5):1509\u201316.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"1668_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/0272989X15622186","volume":"36","author":"ECF Wilson","year":"2016","unstructured":"Wilson ECF, Mugford M, Barton G, Shepstone L. Efficient research design: using value-of-information analysis to estimate the optimal mix of top-down and bottom-up costing approaches in an economic evaluation alongside a clinical trial. Med Decis Making. 2016;36(3):335\u201348.","journal-title":"Med Decis Making"},{"issue":"2 Suppl.","key":"1668_CR21","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","volume":"18","author":"AA Stinnett","year":"1998","unstructured":"Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2 Suppl.):S68-80.","journal-title":"Med Decis Making"},{"issue":"10","key":"1668_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103. https:\/\/doi.org\/10.1001\/jama.2016.12195.","journal-title":"JAMA"},{"issue":"1","key":"1668_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40290-022-00456-6","volume":"37","author":"A Dang","year":"2023","unstructured":"Dang A. Real-world evidence: a primer. Pharm Med. 2023;37(1):25\u201336.","journal-title":"Pharm Med"},{"issue":"6","key":"1668_CR24","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/0272989X11399921","volume":"31","author":"C McKenna","year":"2011","unstructured":"McKenna C, Claxton K. Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis. Med Decis Making. 2011;31(6):853\u201365. https:\/\/doi.org\/10.1177\/0272989X11399921.","journal-title":"Med Decis Making"},{"issue":"3","key":"1668_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0272989X07312724","volume":"28","author":"Z Philips","year":"2008","unstructured":"Philips Z, Claxton K, Palmer S. The half-life of truth: what are appropriate time horizons for research decisions? Med Decis Making. 2008;28(3):287\u201399.","journal-title":"Med Decis Making"},{"issue":"1","key":"1668_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/0272989X07308751","volume":"28","author":"E Fenwick","year":"2008","unstructured":"Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Med Decis Making. 2008;28(1):21\u201332. https:\/\/doi.org\/10.1177\/0272989X07308751.","journal-title":"Med Decis Making"},{"issue":"3","key":"1668_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/0272989X07312477","volume":"28","author":"S Eckermann","year":"2008","unstructured":"Eckermann S, Willan AR. The option value of delay in health technology assessment. Med Decis Making. 2008;28(3):300\u20135.","journal-title":"Med Decis Making"},{"issue":"11","key":"1668_CR28","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0064","volume":"13","author":"NS Levy","year":"2024","unstructured":"Levy NS, Arena PJ, Jemielita T, et al. Use of transportability methods for real-world evidence generation: a review of current applications. J Comp Eff Res. 2024;13(11):e240064. https:\/\/doi.org\/10.57264\/cer-2024-0064.","journal-title":"J Comp Eff Res"},{"issue":"12","key":"1668_CR29","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s40273-023-01303-5","volume":"41","author":"B Jiao","year":"2023","unstructured":"Jiao B. Estimating the potential benefits of confirmatory trials for drugs with accelerated approval: a comprehensive value of information framework. Pharmacoeconomics. 2023;41(12):1617\u201327.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1668_CR30","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/hec.4932","volume":"34","author":"B Jiao","year":"2025","unstructured":"Jiao B, Hsieh YL, Li M, Verguet S. Value-based pricing for drugs with uncertain clinical benefits. Health Econ. 2025;34(4):780\u201390. https:\/\/doi.org\/10.1002\/hec.4932.","journal-title":"Health Econ"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01668-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01668-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01668-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:21:37Z","timestamp":1791552097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01668-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":30,"alternative-id":["1668"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01668-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"24 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Boshen Jiao, Yizhi Liang, Liyuan Tao, and Zafar Zafari have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required. This study did not involve human participants, identifiable personal data, or animal subjects.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No primary data were used in this study. The case study was based on stylized parameter inputs drawn from the published literature and assumptions specified in the article.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The code is available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study\u2019s conception and design. BJ and ZZ led the methodological development. BJ and YL conducted the formal analysis. YL, LT, and ZZ contributed to the model specification, interpretation of results, and critical review of the methodology. BJ drafted the manuscript, and all authors revised it critically for important intellectual content. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}